Advanced Proteome distribution of Linceis shares
Advanced Proteome distribution of Linceis shares 2023-03-08 20:34 ET The TSX Venture Exchange has accepted for filing documentation pertaining to the plan of arrangement of Advanced Proteome Therapeutics Corp. under Section 288 of the Business Corporations Act (British Columbia), as further described in the company's information circular dated Jan. 17, 2023. In connection with the closing of the plan of arrangement, the company has declared a distribution of the common shares of Linceis Capital Corp. on a 1:1 basis. For further information, refer to the company's information circular dated Jan. 17, 2023, and news releases dated Jan. 17, 2023, and March 6, 2023, available on the company's profile on SEDAR. The payable date, record date, due-bill trading date, ex distribution date and due-bill redemption date are as set forth below. Distribution per common share: one common share of Linceis Capital Payable date: March 15, 2023 Record date: March 13, 2023 Due-bill trading date: March 10, 2023 Ex distribution date: March 16, 2023 Due-bill redemption date: March 17, 2023 The company has declared a distribution, per common share held in the company, of one common share of Linceis Capital, which is payable on March 15, 2023, to shareholders of record as of the date of the close of business on March 13, 2023. The common shares of the company will commence trading on a due-bill basis effective from the opening on March 10, 2023, until March 15, 2023, inclusively. Sellers of the shares from March 10, 2023, to and including March 15, 2023, will not be entitled to the distribution. The shares will commence trading on an ex distribution basis effective at the opening on March 16, 2023.